CN1233361C - Traditional Chinese medicine composition for treating cardiovascular disease - Google Patents

Traditional Chinese medicine composition for treating cardiovascular disease Download PDF

Info

Publication number
CN1233361C
CN1233361C CN 03109872 CN03109872A CN1233361C CN 1233361 C CN1233361 C CN 1233361C CN 03109872 CN03109872 CN 03109872 CN 03109872 A CN03109872 A CN 03109872A CN 1233361 C CN1233361 C CN 1233361C
Authority
CN
China
Prior art keywords
treatment
heart
group
chinese medicine
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN 03109872
Other languages
Chinese (zh)
Other versions
CN1537554A (en
Inventor
怀化
李文军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Joyfar Pharmaceutical Co ltd
Original Assignee
Jiufang Pharmaceutical Co Ltd Gujing Group Anhui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiufang Pharmaceutical Co Ltd Gujing Group Anhui filed Critical Jiufang Pharmaceutical Co Ltd Gujing Group Anhui
Priority to CN 03109872 priority Critical patent/CN1233361C/en
Publication of CN1537554A publication Critical patent/CN1537554A/en
Application granted granted Critical
Publication of CN1233361C publication Critical patent/CN1233361C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a traditional Chinese medicine composition for treating cardiovascular disease, especially coronary heart disease, which is prepared form 30 to 120 parts by weight of astragalus root, 18 to 80 parts by weight of rehmannia root, 12 to 60 parts by weight of ophiopogon root, 6 to 40 parts by weight of Chinese magnoliavine fruit, 18 to 72 parts by weight of red peony root and 12 to 60 parts by weight of cassia twig.

Description

A kind of Chinese medicine composition for the treatment of cardiovascular disease
Invention field
The present invention relates to a kind of treatment cardiovascular disease, especially the Chinese medicine composition of coronary heart disease, cardiomyopathy etc. is called the flourish granule of the heart again.
Background technology
National first population cause of the death statistical result (1984) and 8 years monitoring and statistics results of preceding 10 causes of the death of China resident in 1989 all disclose: China population underlying cause of death center disease of ZANG-organs ranks first since the seventies.Domestic and international in recent years experiment and the clinical research about anti-myocardial damage (necrosis), promotion tissue repair has some new progresses.The research of compound recipe SHENGMAI SAN, coronary disease II number is more deep.But the experimentation of the rat myocardial necrosis due to relevant Chinese herb prevention isoproterenol report is very few.Shanghai College of Traditional Chinese Medicine proves tentatively that with Herba Leonuri treatment rat isoproterenol myocardial ischemia this medicine can improve or recover the electrocardiogram of ischemic myocardial, coronary blood flow increasing.The achievement in research proof Folium Crataegi total flavones of Hunan Medical University can resist the rat myocardial ischemia due to the isoproterenol.The Provincial Medicine Research Institute, Jilin with Radix Ginseng different parts Saponin to the protective effect of rat myocardial necrosis studies have shown that the Radix Ginseng different parts all has protective effect to the rat myocardial necrosis, be good with the Herba Herminii saponin especially.Hospital of report Shanghai Medical Univ attached Xinhua in 1987 finds that from set up amycin cardiomyopathy animal model with rat SHENGMAI SAN has a preventive and therapeutic effect to amycin is myocardiac.Reported that the Shanghai Medical Univ angiocardiopathy institute experimentized to myocarditis with the qi-invigorating herb Radix Astragali and the clinical research confirmation Radix Astragali has protective effect to cardiac damage in 1988.Huashan hospital of report Shanghai Medical Univ in 1989 treats infraction with the Radix Astragali, not only can improve cardiac function, can obviously reduce myocardial infarction patient case fatality rate again.Xiyuan Hospital, Chinese Medicine Academy of China's Chinese herbal medicine is being done a large amount of work aspect the research of the protective effect of cultivating the myocardial cell ischemia injury since 1979.With regard to the above research of doing, generally speaking on the degree of depth and systematic study, also need improve, strive for working out the new drug of preventing and treating myocardial necrosis with motherland's medicine and pharmacology characteristic.
It is the main treatment myocardial necrosis with " blood circulation promoting and blood stasis dispelling " that the inventor studies have shown that single, is difficult to obtain good result.The inventor thinks that myocardial necrosis is because Rong Wei lacks of proper care, and cardiac muscle loses lubricious, due to exopathogen is invaded.So abide by the rule of treatment that Difficult Classic " decreases its heart person; transfer its Rong Wei "; thereby the flourish supporing yang QI invigorating of the compound recipe heart, Yin-heart nurishing that design is formed with medicines such as the Radix Astragali, Radix Rehmanniae, Ramulus Cinnamomi; with cardiac nutrition; in order to do the heart-yin Xu Zhen; heart-yang must be answered, and exempts from the effect of infringement and reach " the flourish heart is set upright " protecting myocardial cell.
Summary of the invention
Therefore purpose of the present invention provides a kind of effective treatment cardiovascular disease, the especially Chinese medicine composition of coronary heart disease, cardiomyopathy etc.
Compositions of the present invention comprises following raw material (by weight):
Radix Astragali 30-120 Radix Rehmanniae 18-80 12-60 Radix Ophiopogonis
Fructus Schisandrae Chinensis 6-40 Radix Paeoniae Rubra 18-72 Ramulus Cinnamomi 12-60
Compositions of the present invention preferably includes (by weight):
Radix Astragali 40-90 Radix Rehmanniae 25-55 16-40 Radix Ophiopogonis
Fructus Schisandrae Chinensis 12-30 Radix Paeoniae Rubra 25-50 Ramulus Cinnamomi 16-40
Compositions of the present invention more preferably comprises (by weight):
Radix Astragali 50-70 Radix Rehmanniae 30-45 20-30 Radix Ophiopogonis
Fructus Schisandrae Chinensis 12-25 Radix Paeoniae Rubra 30-45 Ramulus Cinnamomi 20-30.
Function cures mainly: supporing yang, QI invigorating, yin nourishing.Be used for flaccidity of the heart-yang, coronary artery disease with deficiency of both qi and yin.Card is seen sensation of oppression and faint pain in the chest, and shortness of breath and palpitation is had a dizzy spell, tiredness with no desire to speak, lustreless complexion etc.
Radix Astragali head is stated from " herbal classic "." book on Chinese herbal medicine is newly organized " carries the Radix Astragali can " go into meridian of Hand-SHAO YIN "; " book on Chinese herbal medicine meets the source " carries: " Radix Astragali, all void of energy tonifying five ZANG-organs "; " Records of Tradition Chinese and Western Medicine in Combination " carries: " Radix Astragali can QI invigorating, doublely can rise gas, and kind temperature atmosphere (being pectoral qi) is in the heart sunk "; The Radix Astragali is the QI invigorating key medicine, and the BUZHONG YIQI TANG that Li Dongyuan formulates according to the purport of Huangdi's Internal Classics " damage person's benefit ", " diseases caused by over-strain should be treated by warming " is a monarch drug with Radix Astragali QI invigorating in the side.Radix Rehmanniae head is stated from " herbal classic "." medical science invention " carries: " Radix Rehmanniae start with few the moon ", " main cardiopathia "; " big bright book on Chinese herbal medicine " carries: Radix Rehmanniae " it is bad to control palpitation with fear labor, and cardiopulmonary decrease "; Treatise on Febrile Diseases is controlled the card of irregularly intermittent and regularly intermittent pulse severe palpitation with zhigancao decoction, and the heart-yin is nourished with the Radix Rehmanniae by the side.
Ramulus Cinnamomi head is stated from " herbal classic "." book on Chinese herbal medicine is looked for the truth " carries Ramulus Cinnamomi " go into the flesh table, double go into conscience "; " the Changsha medicine is separated " carries " Ramulus Cinnamomi go into liver man and the promoting the circulation of blood branch, walk meridians and reach Rong Yu "; Speech in the Compendium of Material Medica " the hot sweet big heat of Ramulus Cinnamomi can be declared and lead hundred medicines, promoting blood circulation ".Transferring its Rong Wei method head to see the 53rd " in distinguishing that TAI YANG syndrome is controlled " and " Medical Treasures of the Golden Chamber " it " arthralgia due to stagnation of blood asthenia arteries and veins disease also control the 6th " of treatise on Febrile Diseases original text, all is that monarch drug is intended different channels and transferred its battalion to defend with Ramulus Cinnamomi, opens the beginning of the harmonizing nutrient QI and difensive QI rule of treatment.
We are monarch with the Radix Astragali, and the QI invigorating heart tonifying is with the heart-yang that shakes, and medicines such as Radix Rehmanniae are that the minister assistant is moistened the heart-yin, cardiac nutrition, the benefit blood of being indecisive and changeable, and Ramulus Cinnamomi guides all efficacy of a drug to reach cardiac muscle for making.Then gather the merit of " the flourish heart is set upright " of supporing yang QI invigorating, Yin-heart nurishing protection cardiac muscle altogether.
Can compositions of the present invention be made any dosage form of suitable clinical use, for example granule, pill, tablet, powder, capsule, oral liquid etc. according to conventional method.
For example a kind of method comprises that collecting decoction filters with described raw material water decoction one or many, and filtrate decompression is condensed into fluid extract, and drying is granulated again.
For example another kind of method comprises that collecting decoction filters, and concentrates, and makes oral liquid with described raw material water decoction one or many.
Specific embodiment
Followingly the present invention is described, it should be understood that these embodiment only are used for illustrative purposes, are not construed as limiting the invention with reference to embodiment.
Embodiment 1
Radix Astragali 606g Radix Rehmanniae 364g 242g Radix Ophiopogonis
Fructus Schisandrae Chinensis 182g Radix Paeoniae Rubra 364g Ramulus Cinnamomi 242g
Above Six-element decocts with water three times, and 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, collecting decoction filtered, and filtrate decompression is concentrated into the clear paste that relative density is 1.26 (60 ℃), add ethanol and make that to contain alcohol amount be 75%, supernatant is got in cold preservation 48 hours, filter, filtrate recycling ethanol, and be concentrated into the clear paste that relative density is 1.38 (60 ℃), it is an amount of to add sucrose and dextrin, and mixing is made granule, drying is made 1000g, promptly.
Embodiment 2
Radix Astragali 725g Radix Rehmanniae 335g 202g Radix Ophiopogonis
Fructus Schisandrae Chinensis 162g Radix Paeoniae Rubra 384g Ramulus Cinnamomi 212g
More than six hide, decoct with water three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, collecting decoction filtered, and filtrate decompression is concentrated into the clear paste that relative density is 1.26 (60 ℃), add ethanol and make that to contain alcohol amount be 75%, supernatant is got in cold preservation 48 hours, filter, filtrate recycling ethanol, and be concentrated into the clear paste that relative density is 1.38 (60 ℃), it is an amount of to add sucrose and dextrin, and mixing is made granule, drying is made 1000g, promptly.
Embodiment 3
Radix Astragali 535g Radix Rehmanniae 325g 232g Radix Ophiopogonis
Fructus Schisandrae Chinensis 182g Radix Paeoniae Rubra 354g Ramulus Cinnamomi 222g
Above Six-element decocts with water three times, and 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, collecting decoction filtered, and is concentrated into thick paste, and oven dry is pulverized, and incapsulates.
Embodiment 4
Radix Astragali 535g Radix Rehmanniae 325g 232g Radix Ophiopogonis
Fructus Schisandrae Chinensis 182g Radix Paeoniae Rubra 354g Ramulus Cinnamomi 222g
Above Six-element decocts with water three times, and 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, collecting decoction filtered, and makes oral liquid.
One, the flourish treatment of heart myocardial damage phase ii clinical trial
1, clinical myocardial damage patient 404 examples that cause because of various organic heart diseasies of observing altogether of physical data, the thoracic obstruction (coronary heart disease, angina pectoris, hypertensive cardiopathy etc.) 326 examples, cardiopalmus (cardiomyopathy, myocarditis etc.) 78 examples, wherein male 233 examples, woman's 171 examples, M-F is 1.36: 1.Wherein the strict table of random number of 200 routine inpatients is divided into 1 group of the flourish treatment of the heart (hereinafter to be referred as 1 group of treatment), 100 examples, and propranolol treatment group (hereinafter to be referred as matched group) 100 examples are done contrast for two groups and are observed.All the other 204 examples do not enter the table of random number grouping, but also the patient of flourish treatment is 2 groups of the flourish treatments of the heart (hereinafter to be referred as 2 groups of treatments) diligently, out-patient's 64 examples wherein, inpatient 140 examples, 1 group of the treatment of clothes heart honor and 2 groups of 304 routine patients that combine of treatment are referred to as flourish treatment group (hereinafter to be referred as the treatment group) the patient's sex of the heart, age, source see Table 1,2:
Table 1 patient sex, age and the course of disease distribute
Group The man The woman Mean age (year) Average course of disease (year)
Matched group 62 38 55.71(18-35) 4.47(0.2-25)
Treat 1 group 55 45 55.47(15-79) 4.06(0.1-20)
Treat 2 groups 116 88 56.14(25-82) 4.09(0.1-30)
Table 2
The patient comes source distribution
Group Outpatient service Be in hospital Inpatient's ratio (%)
Matched group 0 100 100
Treat 1 group 0 100 100
Treat 2 groups 64 140 68.38
From table 1,2 as can be seen, matched group is compared at aspects such as sex, age, the courses of disease for 1,2 groups with the treatment group, and is similar substantially.
2, study subject is selected 1. tcm diagnosis, dialectical standard and foundation thereof: according to the flourish phase ii clinical trial plan of heart requirement, according to the function of heart honor, select the patient of all flaccidity of the heart-yang that meets the thoracic obstruction (coronary heart disease), cardiopalmus (other heart disease), type of deficiency of both QI and YIN to be the flourish clinical study subject of the heart.Differential diagnosis in tcm: thoracic obstruction dull pain, shortness of breath and palpitation, have a dizzy spell, tiredness with no desire to speak, lustreless complexion, body of the tongue is red partially, pulse condition is thin and delicate or knot generation according to " new Chinese medicine clinical research guideline ".2. Western medicine diagnose standard and foundation thereof: " coronary heart disease " is according to " name of ischemic heart desease and diagnostic criteria "---International Society of Cardiology and association and World Health Organization's clinical name standardization associating specialist paper (Circulation59:607,1979); Other heart disease all by the same period heart disease diagnosis standard determine.3. case inclusion criteria: meet outside above-mentioned 1,2 specified standard by the requirement of the second stage of clinical program is all, the study subject indispensability has electrocardiogram S-T section, T ripple to become the myocardial damage patient of warp.4. case exclusion standard: with in the room or intraventricular block and other be enough to cause Secondary cases S-T section.T ripple changer.
3, the test method case observation carries out in strict accordance with the phase ii clinical trial plan.404 routine patients' grouping is undertaken by above grouping.1. instructions of taking and dosage: the flourish each 10g of the heart, every day 3 times, propranolol dinitrate tablets, each 10mg, every day 3 times.2. course of treatment: all are tried case all with 1 course of treatment of 6 weeks, serving as 1 course of treatment to sum up unit.3. observation item: all are tried symptom, sign and lab index before and after the treatment of case itemized record: comprise chest pain, cardiopalmus, feel suffocated, dizzy, breathe hard, picture of the tongue, pulse condition, the blood pressure heart rate rhythm of the heart, heart x-ray, Electrocardioscopy; Blood, routine urinalysis, liver, kidney function test; Part patient detects blood plasma lipide peroxide (LPO) content, blood rbc superoxide dismutase (SOD) activity.The honor of the special observation heart is to the Acute Hemodynamic treatment effect of patients with congestive heart failure with to patients with coronary heart disease hemodynamics, rheol influence.And tightly observe untoward reaction and toxicity, side effect after the medication.
Result of the test
Criterion of therapeutical effect and foundation thereof: the criterion of therapeutical effect that the plan of the flourish treatment of heart myocardial damage phase ii clinical trial is formulated, according to " new Chinese medicine clinical research guideline ".The therapeutic effect evaluation of myocardial damage is divided into following 3 grades.Produce effects: respectively lead S-T section, T ripple of clinical symptom disappearance, electrocardiogram recovered the obvious improver of normal ECG (being become upright etc. by inversion as the T ripple).Effectively: doing well,improving is more than 1 grade or 1 grade, though electrocardiogram has improvement, does not reach standard, and as S-T section decline 0.05 ~ 0.1mV that the S-T section that descends goes back up to more than the 0.05mV or raises, the T ripple is shoaled by inversion or be low flat, or upright by low flat change; Though electrocardiogram does not have improvement, the obvious improver of clinical symptoms.Invalid: symptom and electrocardiogram all do not have the improver.
Clinical total effects matched group and 1 group of treatment, the therapeutic effect of treatment group is pressed the clinical efficacy standard determination that the phase ii clinical trial plan is formulated, and analyzes contrast, and the result sees table 3 for details:
Flourish each group of table 3 heart compares with the matched group curative effect
Effect Matched group Treat 1 group The treatment group
Produce effects 26 33 86
Effectively 55 59 203
Invalid 19 8 15
Add up to 100 100 304
Total effective rate (%) 81.00 92.00 95.06
Treat 1 group and matched group comparison, analyze P>0.05 with Ridit
Find out that by table 3 the matched group total effective rate is 81.00%, treating 1 group of total effective rate is 92.00%, treatment group total effective rate 95.06%, illustrate that 1 group of treatment, treatment group and matched group more all are better than matched group, analyze through Ridit for two groups that are divided into by table of random number, treat 1 group with matched group there was no significant difference (P>0.05) relatively.
ECG curative effect result sees table 4 for details.Show 1 group of treatment and treatment group and matched group when treating myocardial damage from table 4, close to Electrocardiographic clinical effective rate.
Flourish each group of table 4 heart compares with the matched group ECG curative effect
Effect Matched group Treat 1 group The treatment group
Produce effects 31 33 86
Effectively 28 31 104
Invalid 41 36 114
Add up to 100 100 304
Total effective rate (%) 59.00 64.00 62.50
Clinical therapeutic effect of syndrome result sees table 5,6 for details:
1 group of disease curative effect of table 5 matched group and treatment relatively
Effect Matched group Treat 1 group
Chest pain Cardiopalmus Feel suffocated Dizzy Breathe hard Add up to Chest pain Cardiopalmus Feel suffocated Dizzy Breathe hard Add up to
78 63 62 43 57 303 75 71 57 57 73 333
Produce effects 61 54 46 30 41 232 68 62 46 48 61 285
Effectively 11 5 10 6 8 40 5 7 7 4 7 30
Add up to 72 59 56 36 49 272 73 69 53 52 68 315
Effectively fill in 92.3 1 93.6 5 90.3 2 83.7 2 85.9 0 89.7 6 97.3 3 97.1 8 92.9 8 91.2 3 93.1 5 95.5 9
Treat 1 group and matched group comparison, analyze P>0.05 with Ridit
Show heart honor when improving myocardial damage from table 5, patient's clinical disease is also had clear improvement, analyze its effect through Ridit and significantly be better than matched group (P<0.05).
The disease curative effect of table 6 treatment group
Effect Chest pain 233 Cardiopalmus 241 Feel suffocated 212 Dizzy 203 Breathe hard 250 Add up to 1139
Produce effects 203 224 193 184 228 1032
Effectively 12 12 11 11 17 63
Add up to 215 236 204 195 245 1095
Effective percentage (%) 92.27 97.93 96.23 96.06 98.00 96.14
Show heart honor when improving patient's myocardial damage from table 6, the influence that clinical disease also is significantly improved to blood pressure, heart rate sees table 7,8 for details:
Blood pressure (X meansigma methods ± s) relatively before and after flourish each group of table 7 heart and the matched group
Group Before the treatment After the treatment t P
Systolic pressure (kpa) Matched group 18.95±2.88 17.05±2.03 3.72 <0.01
Treat 1 group 18.34±2.80 17.35±2.11 3.52 <0.05
The treatment group 17.88±2.89 16.97±2.10 2.78 <0.05
Diastolic pressure (kpa) Matched group 11.55±1.74 10.64±1.15 3.05 <0.01
Treat 1 group 11.19±1.48 10.61±1.25 2.80 <0.05
The treatment group 11.04±1.43 10.51±1.61 2.63 <0.05
Flourish each group of table 8 heart with to (the X meansigma methods ± s) of changes in heart rate before and after the group treatment
Group Before the treatment After the treatment t P
Matched group 84.60±13.71 73.79±9.67 4.86 <0.01
Treat 1 group 81.98±13.41 78.63±8.92 2.06 >0.05
The treatment group 83.21±13.52 76.47±9.03 1.65 >0.05
Treat 1 group and the variation comparison of treatment of control group front and back, t=4.40, P<0.01.
Find that from table 7 each group all has regulating action to patient's blood pressure.Table 8 shows that matched group has the effect of remarkable inhibition heart rate, makes decreased heart rate, and flourish each group of the heart does not then have this effect, treat 1 group with matched group relatively, significant differences (P<0.01) is arranged.
1. laboratory checking index changes treats 1 group and 2 groups of blood, routine urinalysis with matched group patient treatment front and back of treatment and does not have influence.2. heart x-ray diagnosis is treated 1 group and treatment group and is not had obvious influence with matched group patient treatment front and back X line.3. the heart flourish with the influence of propranolol to erythrocyte sod enzyme and blood plasma LPO: carried out the analysis contrast before and after the treatment to treating 1 group and matched group, the result sees table 9,10 for details:
Erythrocyte sod variation before and after 1 group of table 9 treatment and the matched group (SOD U/mg Hb, the x meansigma methods ± s)
Group N Before the treatment After the treatment t P
High value group Matched group 10 1222.53±43.70 1129.53±43.70 1.40 >0.05
Treat 1 group 12 1189.00±29.64 1107.00±36.60 1.10 >0.05
The low value group Matched group 20 824.63±26.53 869.68±29.35 1.69 >0.05
Treat 1 group 18 862.00±21.53 1002.00±42.37 2.48 <0.01
The low value group compares u=6.47, P<0.01 for two groups
Blood plasma LPO variation comparison before and after 1 group of treatment of control group of table 10 treatment (nmolMAD/ml, the x meansigma methods ± s)
Group N Before the treatment After the treatment t P
High value group Matched group 9 2.75±0.19 12.60±0.17 0.58 >0.05
Treat 1 group 10 2.72±0.16 2.04±0.21 2.60 <0.05
The low value group Matched group 21 1.34±0.08 1.44±0.11 0.71 >0.05
Treat 1 group 20 1.36±0.09 1.47±0.11 0.70 >0.05
High value is organized two groups relatively: u=10, P<0.01
Find that from table 10,11 heart honor has rising low value group patient SOD enzymatic activity, reduce the effect of high value group LPO content, and propranolol is not have this regulating action, two groups relatively have significant differences (P<0.01).
1. analysis of adverse reactions observes by the flourish treatment 304 routine patients of the heart, and the patient feels sick in take medicine just 3 routine xerostomias, 2 examples, 2 routine loose stool, 2 routine constipation, but disappears in the back of continuing to take medicine, and does not see other untoward reaction and toxicity, side effect.2. heart honor to there not being influence before and after patient liver, the renal function curing, is learned by statistics and is handled p<0.05 when the treatment myocardial damage, illustrates that heart honor is to harmless before and after patient liver, the renal function curing, to body safety.
Heart honor can improve cardiac function to the influence of the cardiac function effect according to the flourish supporing yang QI invigorating of the heart, Yin-heart nurishing, and the effect of cardiac function has further been observed in this test again.
Use the SWAN-GANZ catheterization, observing patient's hemodynamics after taking heart honor changes, 32 routine chronic congestion heart failure patient 1~4h after taking medicine, reduction MPAP is arranged, PCWP, improve CI, improve the effect of cardiac function, its result has significant difference with the drinking-water contrast, adopt ZXG-40 noinvasive cardiovascular function diagnostic apparatus, the patients with coronary heart disease of 30 routine myocardial damages has been carried out the cardiac function of the flourish treatment of heart front and back, the variation of microcirculation and blood viscosity is observed, and shows that tentatively heart honor has the heart pump of enhancing function, improve Coronary Perfusion Pressure, strengthen myocardial flow, reduce whole blood viscosity, the effect of microcirculation improvement.
Conclusion
The myocardial damage that different reason organic heart diseasies cause clinically corresponding symptom occurs, itself or cardiac insufficiency, S-T can appear in electrocardiogram, the T ripple changes, by middle-aged and elderly people common.Chinese medicine thinks that primary disease belongs to the thoracic obstruction and cardiopalmus category, and is many because the motive is deficient, and blood is not due to the reason such as Rong Xin.Heart honor has supporing yang QI invigorating, Yin-heart nurishing, cardiac nutrition, alleviates the function of myocardial necrosis, the treatment rule that clinical treatment " decreases its heart person, transfers its Rong Wei " by Chinese medicine.To 304 routine myocardial damage patient experimental observation results be: produce effects 86 examples, effective 203 examples, invalid 15 examples, total effective rate 95.06%.Electrocardiogram produce effects 86 examples, effective 104 examples, invalid 114 examples, total effective rate 62.50%.By 1 group of the flourish treatment of the heart and each 100 routine comparative observation of contrast medicine propranolol matched group, the curative effect that total effects that the flourish treatment of the heart is 1 group and disease curative effect are better than the propranolol matched group.In the 304 routine patients that take the flourish treatment group of the heart, except that there being 9 routine patients to occur xerostomia, constipation and the diarrhoea other untoward reaction and toxicity, side effect not taking place at the initial stage of taking medicine.
The flourish treatment of heart myocardial damage patient experimental observation shows, this medicine has no adverse effects to patient's routine blood test and liver, renal function.The clinical trial of the flourish treatment of heart myocardial damage is observed and is shown, this medical instrument has the good functions such as patient's clinical symptoms, blood pressure regulation, improvement cardiac muscle microcirculation disturbance of improving, to then not obviously influence of heart rate.Also observe simultaneously, this medicine has the blood rbc of raising SOD enzymatic activity, reduces the effect of blood plasma LPO content, and its effect obviously is better than contrasting the medicine propranolol, illustrates that this medicine has the myocardium effect that resists damage and promote the myocardial cell reparation of raising.Show that by part patient's hemodynamics is observed heart honor has the pulmonary artery pressure of reduction and its wedge pressure of pulmonary capillary, raising heart row blood index etc. improves the effect of cardiac function, shows that heart honor has positive inotropic action.So we can affirm: heart honor is the active drug of the myocardial damage that causes of the various organic heart diseasies of treatment, and clinical total effective rate is 95.06%; Electrocardiogram total effective rate 62.50%.The flourish no toxicity, side effect of the heart facilitates patients.
Two, the clinical trial of the flourish treatment of heart myocardial ischemia
Data and method
Since November nineteen ninety, diligently flourish treatment is organized: male 33 examples as treatment because of inpatient 52 examples of myocardial ischemia due to the various heart diseases, woman's 19 examples, at 19~74 years old age (average 49.8 years old), the cause of disease has angina pectoris, old myocardial infarction 21 examples, acute myocardial infarction 6 examples, hypertensive cardiopathy 3 examples, cardiomyopathy 11 examples, myocarditis 10 examples, rheumatic heart disease 1 example.Matched group 15 examples are all with propranolol treatment, wherein male 7 examples, women 8 examples, age 13-72 year (average 43.8 years old), coronary heart disease 8 examples, cardiomyopathy 5 examples, rheumatic heart disease 2 examples.
The each patient is admitted to hospital after detailed medical history-taking, have a medical check-up, the film making of electrocardiogram, heart, echocardiography, part patient has also done myocardial enzymes, angiocardiography inspection.Coronary heart disease is undertaken by the WHO diagnostic criteria, other heart disease all by the same period cardiovascular diagnosis standard determine.Electrocardiogram criterion: S-T section rising 〉=0.1mV, descending is horizontal type or declivity type 〉=0.05mV, the smooth or inversion of T popin.
Heart honor is made up of a few flavor Chinese medicines such as the Radixs Astragali, and by the marmite slow fire boiling of traditional Chinese medical science traditional method, front and back decoct twice medicinal liquid mixing, and concentrated acid becomes per ampoule 10ml, each 20ml.3 times/d, 4 weeks were 1 course of treatment.Propranolol 5-10mg, 3 times/d, 4 weeks were 1 course of treatment.The each patient respectively does 1 part of 12 lead electrocardiogram 1,2,3,4 weekends before medication, after the medication, and part patient respectively inspects myocardial enzymes by ready samples before and after medication.
The curative effect determinate standard produce effects: transference cure, electrocardiogram S-T section, T ripple recover normal; Effectively: doing well,improving, electrocardiogram S-T section or T ripple have two above recoveries of leading normally or partly to improve (flattened by inversion as the T ripple, the S-T section is by more than the former decline level rising 0.05mV); It is invalid: though symptom has part to improve S-T section, T ripple no change.
The result
Heart honor is 89.07% (seeing Table 11) to the effective percentage of doing well,improving, and electrocardiogram produce effects 9.68% is effective 32.25%, and is invalid 58.07%, electrocardiogram total effective rate 41.93%.The effective percentage that propranolol improves symptom is 68.57% (seeing Table 12), electrocardiogram obvious effective rate 39.99%, invalid 60.01%.
Doing well,improving situation before and after the flourish treatment 52 routine myocardial ischemia of table 11 heart
Dizzy Cardiopalmus Breathe hard Uncomfortable in chest Inappetence Weak Add up to example inferior
Before the treatment 15 38 23 40 18 13 147
After the treatment Improve 15 32 18 38 14 11 128
Do not improve 0 6 5 2 2 2 19
Table 12 propranolol is treated 15 routine myocardial ischemia front and back doing well,improving situations
Dizzy Cardiopalmus Breathe hard Uncomfortable in chest Inappetence Weak Add up to example inferior
Before the treatment 3 14 7 5 4 2 35
After the treatment Improve 2 13 4 3 1 1 24
Do not improve 1 1 3 2 3 1 11
Myocardial damage, myocardial ischemia are clinical common performances due to coronary heart disease and other heart disease, previously many grade with vasodilation, beta-blocker, calcium antagonist improved myocardial ischemia, myocardial damage, Chinese medicine aspect use the treatment of " activating blood circulation to dissipate blood stasis " prescription all to obtain certain curative effect more.Heart Rong Ze starts with from " the flourish heart is set upright ", and the mechanism of the flourish treatment of animal experiment proof heart myocardial ischemia is to improve myocardium microcirculation, promotes myocardial metabolism; improve blood gst enzyme contents level; participate in oxidation-reduction system, thereby play the protection cardiac muscle, and improve cardiac muscle anoxybiotic toleration.As everyone knows, propranolol then is with decreasing heart rate, lowers myocardial contraction, reduces myocardial oxygen consumption, and improves cardiac muscle to anoxybiotic tolerance.Clinical observation shows that heart honor all has certain curative effect to myocardial ischemia, myocardial damage due to the various heart diseases, but to myocardial ischemia, myocardial damage better efficacy due to myocarditis, the angina pectoris.The flourish determined curative effect of the heart.All be better than propranolol aspect the symptom electrocardiogram improving, and easy to use, have no side effect.Heart honor is compared with the DIAOXINXUE KANG that Chengdu, Sichuan produces, and the former is 87.07% for the symptom effective percentage, and the latter 87.8%, and both are similar.Electrocardiogram effective percentage heart honor 41.93%, DIAOXINXUE KANG 50%.This may be relevant with the flourish short treating period that uses of the heart.
Three, the contrast test of heart honor and propranolol treatment myocardial damage heart disease curative effect
Myocardial damage patient 84 examples that the clinical data clinical observation causes because of the thoracic obstruction (coronary heart disease).Observe for the systematicness that guarantees to treat, all cases all derive from the inpatient, and wherein 60 routine patients are divided into the flourish treatment of the heart in strict accordance with table of random number and organize 30 examples (hereinafter to be referred as the treatment group), do contrast for two groups and observe.All the other do not enter the table of random number grouping, but the also flourish diligently 24 routine patients that treat are the flourish open treatment group of the heart.
Treatment is organized among the 30 routine patients, male 14 examples, women 16 examples, the oldest 75 years old, minimum 43 years old, 57.6 years old mean age.The course of disease is the longest 20 years, and is the shortest 0.25.
Among the matched group 30 routine patients, male's 18 examples, women's 12 examples, oldest 75 years old, minimum 0.1 year.
Test method
1, instructions of taking and dosage treatment group are taken heart honor, each 0.42g*5 capsules, every day 3 times, matched group propranolol dinitrate tablets, each 10mg/ sheet, every day 3 times.
2, the course of treatment all to be tried case be a course of treatment with 6 weeks all, serving as a course of treatment to sum up unit.
3, observation item heart rate, sign such as blood pressure, picture of the tongue, pulse condition and blood, routine urinalysis, biochemical indicators such as liver function, and tightly observe untoward reaction and the toxicity, side effect that occurs after the medication.
Result of the test
1, criterion of therapeutical effect and foundation thereof
2, formulate the plan of the flourish treatment of heart injury of myocardium phase ii clinical trial according to " new Chinese medicine clinical research guideline ", the therapeutic effect evaluation of myocardial damage is divided into 3 grades:
Produce effects: respectively lead S-T section, T ripple of clinical symptom disappearance, electrocardiogram recovered normal or electrocardiogram obviously improves (becoming low equality by inversion as the T ripple).
Effectively: doing well,improving one-level or more than the one-level, though electrocardiogram has improvement, do not reach standard, go back up to more than the 0.05mV as the S-T section that descends, or the S-T section decline 0.05-0.01mV that raises, the T ripple is flat or flatly become upright by low by being inverted step-down; Though or electrocardiogram does not have improvement, the obvious improver of clinical symptoms.
Invalid: symptom and electrocardiogram all do not have obvious improver.
A, clinical total course of treatment the results are shown in Table 13
The flourish total effective rate 93.33% of the heart, 63.335%, two group of curative effect of propranolol aggregate efficiency compares, and the treatment group is better than matched group, and significant difference (P<0.01) is arranged.
Table 13 treatment group and matched group curative effect are relatively
Group n Produce effects Effectively Total effective rate
The treatment group 30 12(40.00%) 16(53.33%) 28(93.33%)
Matched group 30 7(23.33%) 12(40.00%) 19(63.33%)
* through x 2Check: x 2=9.93, p<0.01
B, ECG curative effect the results are shown in Table 14:
Table 14 treatment group and matched group ECG curative effect are relatively
Group n Produce effects Effectively Invalid Effective percentage (%)
The treatment group 30 11 8 11 63.33
Matched group 30 6 11 5 56.67
As can be seen from Table 14, two groups that electrocardiogram is improved situation is similar.
C, clinical disease efficacy result see Table 15:
The curative effect of table 15 treatment group and the clinical syndrome of matched group relatively
Matched group The treatment group
Effect Chest pain 28 Cardiopalmus 26 Feel suffocated 29 Dizzy 15 Breathe hard 20 Add up to 118 Chest pain 28 Cardiopalmus 24 Feel suffocated 27 Dizzy 19 Breathe hard 22 Add up to 120
Produce effects 30 17 14 10 6 67 19 15 19 12 20 25
Effectively 5 7 3 2 7 29 7 8 7 5 1 28
Add up to 25 24 22 12 13 96 26 23 26 17 21 113
Effective percentage (%) 89. 29 92 .30 75. 86 80. 00 65. 00 21. 35 92. 86 95. 83 96. 47 89. 47 95. 45 94. 17
Through x 2Check: x=1.32, p<0.05
D, to the influence of blood pressure, heart rate
Our primary part observation treatment group and matched group patient blood pressure and changes in heart rate situation, two groups of blood pressure effects that all show the patient that has some improvement then do not have obvious influence to patient's heart rate treatment group, matched group then has significant decreased heart rate effect.The results are shown in Table 16:
Table 16 treatment group and matched group are to the influence of blood pressure (x meansigma methods ± s)
Group N Before the treatment After the treatment t P
Systolic pressure Matched group 30 18.34±2.63 17.91±1.74 2.14 <0.05
Treat 1 group 30 19.34±2.57 17.26±1.90 3.46 <0.001
Diastolic pressure Matched group 30 11.52±1.53 10.62±1.27 2.7 <0.05
Treat 1 group 30 11.89±1.92 10.70±1.79 2.97 <0.01
E, laboratory checking index change hepatic and renal function before and after 1. treatment group and the matched group and blood, routine urinalysis is not seen significant change.2. treatment group and matched group in patient's breast sheet, cardiothoracic ratio unusual person carried out before and after the treatment observation relatively, observation shows, the unusual person of two groups of patients' cardiothoracic ratio does not have significant change after 1 course of treatment, and effective percentage is respectively more also zero difference of 9.90% and 12.50%, two group of treatment back.3. treatment group, matched group are to the influence of erythrocyte superoxide dismutase (SOD) and peroxide plasma (LPO).In clinical, we compare SOD and the LPO before and after treatment group, the matched group patient, find that heart honor has the effect of rising low value group patient SOD and the high value group patient blood plasma LPO of reduction.
The relation of F, course of disease curative effect is from the experimental data analysis, in the treatment group produce effects 12 routine courses of disease, its morbidity of 8 examples is arranged in 2 years, account for produce effects patient's 66.68%, illustrate that disease time and curative effect have significant dependency, the course of disease is short more, it is good more to take this drug effect fruit, in 2 routine invalid cases, and 5 years medical history 1 examples, 7 years case 10 examples also illustrate that curative effect is relevant with the course of disease.
Therapeutic effect and age do not have obvious relation.
Conclusion
1, should flourishly diligently treat the myocardial damage patient that the thoracic obstruction (coronary heart disease) causes, clinical observation, 54 examples, produce effects 21 examples, effective 27 examples, total effective rate 90.74% are organized in treatment, electrocardiogram produce effects 19 examples, effective 17 examples, total effective rate 66.67% compares at random through 30 routine treatment groups and 30 routine matched groups, effect obviously is better than the propranolol matched group, and has no adverse reaction and the toxic and side effects generation.
2, heart honor is in treatment myocardial damage patient procedure, and to patient's blood, routine urinalysis, liver, renal function do not have obvious influence.
3, the flourish treatment of heart myocardial damage shows that through clinical observation this medical instrument has the effect of supporing yang QI invigorating, Yin-heart nurishing.
Show by clinical observation, this medicine has the therapeutic effect that improves the erythrocyte sod enzymatic activity and reduce blood plasma LPO content, has the myocardium microcirculation disturbance of adjusting, improve Electrocardiographic effect, the blood pressure of regulating patient is also arranged simultaneously, recover the equilibrated function of patient's each internal organs of body, reach the effect of treatment myocardial damage.
Four, oral heart honor is to the clinical trial of patients with coronary heart disease plasma viscosity influence
Object this paper is selected in 105 routine patients, age 55-70 year, and male 70 examples, women 35 examples are all made a definite diagnosis by the WHO diagnostic criteria for coronary heart disease.The angina pectoris history of attack is arranged in the recent period, the blood drawing chemical examination high blood viscosity on an empty stomach of wherein being admitted to hospital: male 45 examples, women 20 examples (for adopting the chemical examination of NXE-1 type cone and plate viscometer before taking medicine).
The 2ml that draws blood on an empty stomach before method is taken medicine to selected patient adopts the chemical examination of NXE-1 type cone and plate viscometer, method of administration: the flourish granule of the oral heart, every day three times, behind the course of treatment 40d, 2ml once more on an empty stomach draws blood, still adopt the cone and plate viscometer chemical examination, data are adopted the classified statistics analysis.
The relevant significant t-test of statistics.
The results are shown in Table 17,18:
Plasma viscosity before and after table 17 is taken medicine (nPa-s, x ± s)
n The preceding blood of taking medicine After taking medicine The P value
The man 70 1.61±0.11 1.57±0.05 <0.05
The woman 45 1.48±0.07 1.42±0.11 <0.05
Plasma viscosity before and after table 18 high blood viscosity patient takes medicine (nPa-s, x ± s)
n The preceding blood of taking medicine After taking medicine The P value
The man 45 1.68±0.14 1.59±0.16 <0.05
The woman 20 1.54±0.13 1.42±0.15 <0.05
Can find above data statistic analysis and relevant significance test: 1. obey the heart after flourish 40 days, two groups of plasma viscosities of men and women all reduce, with take medicine before with the gender group significance test significant difference is arranged.2. high blood viscosity patient plasma viscosity equally also reduces, with general patients with gender group significance test there was no significant difference.Heart honor can reduce patient's plasma viscosity, and is relevant with the flourish pharmacological action of the heart own: the activity of rising people's erythrocyte sod enzyme.Reduce people's LPO (lipid peroxide) contents level.Reduce animal FFA (free fatty).Reduce animal aliphatic peroxide-TBA value.Heart honor can delay the evolution process of coronary heart disease to the preventive effect that has of coronary heart disease, prevents the generation of myocardial infarction.
Five, heart honor is to patients with coronary heart disease hemodynamic, rheol influence
ZXG-4C noinvasive cardiovascular function diagnostic apparatus (production of Anhui Electronic Computer Factory) is adopted in this research, and the non-invasive detection has been carried out in the aspects such as cardiac function, vascular function, microcirculation function parameter and blood viscosity parameter before and after the honor of the patients with coronary heart disease clothes heart.
The materials and methods patients with coronary heart disease is all determined by the WHO diagnostic criteria.Male 18 examples, women 12 examples, 56.8 years old mean age, angina pectoris 15 examples, cardiac arrhythmia 10 examples, complicated hypertension 10 examples are treated in motive honor to 30 routine patients with coronary heart disease in March, 1993 to July.All detect cardiac functional parameter all in abnormal ranges before the case treatment.The course of disease is the shortest 21 days, and is the longest 15 years.Flourish each 1 bag of the heart 3 times/d, is obeyed 1 course of treatment (42d), other dilator of stopping using during the treatment altogether.Use ZXG-4C noinvasive cardiovascular function diagnostic apparatus before and after the treatment, from hemodynamic Research on The Rheology angle, to patient's cardiac function, vascular function, microcirculation function and blood viscosity parameter detect and verify.
The result as seen from Table 19, careful flourish treatment back patient's pulse frequency (PR), the spray blood impedance (VER) of left chamber, myocardial oxygen consumption (HOV) all significantly slows down or reduce (P<0.05 or P<0.005); Whenever the stroke volume of fighting (SV), heartbeat index (SWI), cardiac index (CI), the effective pump power in left chamber (VPE), left ventricle energy effective utilization rate (EWK), arteria coronaria are fought perfusion pressure (CCP), myocardial blood for consumption rate (CMBR) be significantly increased (P<0.05 or P<0.01 or P<0.001).As seen from Table 20, careful flourish treatment back patient's pulmonary artery pressure (PAP), pulmonary vascular resistance (PAR), blood vessel elasticity flare factor (FEX), week resistance (TPR) always, the equal highly significant of standard week resistance (SPR) reduce (P<0.005 or P<0.001).As seen from Table 21, careful flourish treatment back patient's whole blood viscosity and reduced blood viscosity all have remarkable reduction (P<0.05 or P<0.01).As seen from Table 22, patient's microcirculation turnover rate (MHR) microcirculation half update time (MRT), microcirculation mean residence time (MST) all significantly reduce (P<0.05 or P<0.01) after the careful flourish treatment.
The honor of table 19 heart is to the influence of heart function parameter (x ± s)
Project Normal value Before the treatment After the treatment P
PR 70 ± 10 times/minute 71.17±1.987 68.6±1.947 <0.005
SV 80-90ml/L 71.85±1.98 92.31±1.76 <0.05
SWI 70-90Gm/b/m 2 68.78±1.872 82.035±1.192 <0.05
CI 3-7L/min/m 2 2.840±0.227 3.757±0.159 <0.01
VPE 1.8kg/b 1.756±0.161 2.027±0.0635 <0.05
HOV 21.85-40.79ml/min 41.48±1.923 39.63±1.771 <0.05
EWK 0.28-0.30 0.2739±0.0073 0.2935±0.07739 <0.05
VER 160-220dyn.s.cm 2 230.26±7.50 1.883±7.49 <0.005
CCP 6.65-9.31kpa 6.057±0.663 8.037±0.543 <0.001
CMBR ≥1 0.8307±0.0126 1.144±0.0123 <0.001
The honor of table 20 heart is to the influence of blood vessel parameter (x ± s)
Project Normal value Before the treatment After the treatment P
FEK 0.35-0.55 0.2424±0.0263 0.407±0.053 <0.005
PAP 2-4kpa 4.670±0.1287 2.633±0.08436 <0.005
PAR 100-300dyn.s.cm -5 303.87±43.64 164.206±26.5 <0.005
TPR 800-1300dyn.s.cm -5 1569.5±128.908 1191.1±58.54 <0.005
SPR 900-1400dyn.s.cm -5 1565.2±120.146 1135.9±63.726 <0.005
The honor of table 21 heart is to the influence of blood viscosity parameter (x ± s)
Project Normal value Before the treatment After the treatment P
η 3-4mpa.s 4.7501±0.0078 3.2723±0.1298 <0.05
ηr 3-4mpa.s 4.367±0.434 3.395±0.164 <0.01
The honor of table 22 heart is to the influence of circulatory function parameter (x ± s)
Project Normal value Before the treatment After the treatment P
MHR 0.04-0.08 0.06628±0.01973 0.0461±0.00202 <0.05
MRY 10-20S 24.895±2.7209 18.257±1.604 <0.05
MST 15-30S 33.46±2.48 23.404±1.429 <0.02
Brief summary
Can improve the rich perfusion pressure (CCP) of coronary artery, myocardial oxygen consumption is reduced, myocardial blood recovers normal for the consumption rate, and myocardium blood-pumping function obviously improves.Heart honor may be relevant with its improvement cardiac muscle biochemical metabolism to cardiac pump function mechanism.Heart honor can reduce left chamber pump blood impedance (VER), lung A presses (PAP), total week resistance (TPR) etc., thereby the improvement of prompting cardiac pump function is also relevant with its blood vessel dilating effect.Heart honor can reduce whole blood viscosity and reduction whole blood viscosity and microcirculation improvement function.

Claims (8)

1, a kind of Chinese medicine composition that is used for the treatment of cardiovascular disease, make by following raw material by weight:
Radix Astragali 30-120 Radix Rehmanniae 18-80 12-60 Radix Ophiopogonis
Fructus Schisandrae Chinensis 6-40 Radix Paeoniae Rubra 18-72 Ramulus Cinnamomi 12-60.
2,, it is characterized in that the weight portion of described raw material is according to the Chinese medicine composition that is used for the treatment of cardiovascular disease of claim 1:
Radix Astragali 40-90 Radix Rehmanniae 25-55 16-40 Radix Ophiopogonis
Fructus Schisandrae Chinensis 12-30 Radix Paeoniae Rubra 25-50 Ramulus Cinnamomi 16-40.
3,, it is characterized in that the weight portion of described raw material is according to the Chinese medicine composition that is used for the treatment of cardiovascular disease of claim 2:
Radix Astragali 50-70 Radix Rehmanniae 30-45 20-30 Radix Ophiopogonis
Fructus Schisandrae Chinensis 12-25 Radix Paeoniae Rubra 30-45 Ramulus Cinnamomi 20-30.
4, according to each Chinese medicine composition among the claim 1-3, wherein said cardiovascular disease is a coronary heart disease.
5, according to each Chinese medicine composition among the claim 1-3, wherein said cardiovascular disease is a cardiomyopathy.
6,, be characterised in that it is any peroral dosage form that is suitable for clinically according to each Chinese medicine composition among the claim 1-3.
7, the method for each Chinese medicine composition among the preparation claim 1-3 comprises described raw material water is decocted one or many, and collecting decoction filters, and filtrate decompression is condensed into fluid extract, and drying is granulated again.
8, the method for each Chinese medicine composition among the preparation claim 1-3 comprises described raw material water is decocted one or many that collecting decoction filters, and concentrates, and makes oral liquid.
CN 03109872 2003-04-16 2003-04-16 Traditional Chinese medicine composition for treating cardiovascular disease Expired - Lifetime CN1233361C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 03109872 CN1233361C (en) 2003-04-16 2003-04-16 Traditional Chinese medicine composition for treating cardiovascular disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 03109872 CN1233361C (en) 2003-04-16 2003-04-16 Traditional Chinese medicine composition for treating cardiovascular disease

Publications (2)

Publication Number Publication Date
CN1537554A CN1537554A (en) 2004-10-20
CN1233361C true CN1233361C (en) 2005-12-28

Family

ID=34319548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 03109872 Expired - Lifetime CN1233361C (en) 2003-04-16 2003-04-16 Traditional Chinese medicine composition for treating cardiovascular disease

Country Status (1)

Country Link
CN (1) CN1233361C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100333750C (en) * 2005-06-02 2007-08-29 赵东科 Traditional Chinese medicine preparation for treating thoracic obstruction and palpitation and preparation method thereof
CN106728946A (en) * 2017-01-24 2017-05-31 贵州省武陵山药用植物白芨开发有限公司 Dendrobium officinale health wine composition, dendrobium officinale health wine and preparation method thereof
CN114042121A (en) * 2021-11-18 2022-02-15 杜恒 Sustained-release pellet preparation for treating chronic congestive heart failure and preparation method thereof

Also Published As

Publication number Publication date
CN1537554A (en) 2004-10-20

Similar Documents

Publication Publication Date Title
CN1259935C (en) Medicine for treating hyperlipemia
CN1915399A (en) Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method
CN1240416C (en) Medicine for curing hypertension and its preparation method
CN102160884A (en) Chinese medicinal preparation for treating acute period vital myocarditis
CN1709404A (en) Chinese patent medicine for preventing and treating apoplexia disease, and its production method and use
CN1726929A (en) Compsn. of medication for treating diabetes
CN1927331A (en) Chinese medicine preparation for curing chronic heart failure
CN1733242A (en) Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same
CN1233361C (en) Traditional Chinese medicine composition for treating cardiovascular disease
CN104147346B (en) It is a kind of to treat the anginal Chinese medicine compound prescription of coronary artery diffusivity lesion
CN1718193A (en) Total secondary ginseng glucoside medicine composition, its prepn. method and application in preparing medicine for treating myocardial ischemia and hemorrhagic shock
CN100344304C (en) Traditional Chinese medicine preparation for treating consumptive disease and preparation method thereof
CN105456689A (en) Traditional Chinese medicine composition for treating diabetes as well as preparation method and application of traditional Chinese medicine composition
CN102048939B (en) Medicament for treating sinus bradycardia
CN1660387A (en) Health care preparation for regulating functional balance of organs of bowels in human body and preparing method
CN102049010B (en) Medicament for preventing and treating ischemic cerebrovascular diseases
CN1990033A (en) Drug for treating hypertension, dense blood and arteriosclerosis
CN1686485A (en) Medicinal composition for treating coronary heart disease and stenocardia and its preparation method
CN104587387B (en) A kind of combined traditional Chinese medicine and preparation method for preventing and treating three high diseases
CN1682892A (en) Tengdan capsule for treating hypertension
CN107281386A (en) Method and the application for the treatment of hypertension drug are prepared with dendrobium candidum and radish seed
CN102671056A (en) Chinese medicinal composition for treating hepatitis and preparation method thereof
CN1227023C (en) Drug for treating coronary heart disease, angina and preparation method
CN1276764C (en) Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia
CN101361797A (en) Traditional Chinese medicine pressure-reduction insoles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ANHUI JIUFANG PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: JIUFANG PHARMACEUTICAL CO LTD, GUJING GROUP, ANHUI

CP01 Change in the name or title of a patent holder

Address after: Bozhou Economic Development Zone, Anhui

Patentee after: ANHUI JOYFAR PHARMACEUTICAL CO.,LTD.

Address before: Bozhou Economic Development Zone, Anhui

Patentee before: Anhui Gujing Group Jiufang Pharmaceutical Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20051228

CX01 Expiry of patent term